�Micromet, Inc.
(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary
antibodies for the of MT203, a human
antibody neutralizing the activeness of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in the
treatment of various rabble-rousing and autoimmune diseases, such as
rheumy arthritis, psoriasis, or multiple sclerosis.
Forward Looking Statements
This release contains certain modern statements that involve
risks and uncertainties that could cause existent results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. These forward-looking
statements admit statements regarding the efficaciousness, safety and intended
utilization of our product candidates, the development of our BiTE antibody
technology, the conduct, timing and results of succeeding clinical trials,
expectations of the future expansion of our product pipeline and
collaborations, and our plans regarding future presentations of clinical
data. You ar urged to consider statements that include the words
"ongoing," "whitethorn," "will," "believes," "potential," "expects," "plans,"
"anticipates," "intends," or the negative of those words or other similar
words to be uncertain and forward-looking. Factors that may grounds actual
results to dissent materially from any succeeding results expressed or implied
by any forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or clinical
trials do not attest safety and/or efficacy in subsequent clinical
trials, the risk that encouraging results from early research, preclinical
studies or clinical trials may non be confirmed upon further analysis of
the elaborate results of such research, preclinical survey or clinical trial,
the risk that additional info relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial run data, the risk that we or our
collaborators will non obtain blessing to grocery store our product candidates,
the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborators,
including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialisation activities relating to
our product candidates. These factors and others are more fully discussed
in Micromet's Annual Report on Form 10-K for the fiscal year terminated December
31, 2007, filed with the SEC on March 14, 2008, as well as other filings by
the company with the SEC.
Any advanced statements ar made pursuant to Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and, as such, speak only as of the escort
made. Micromet, Inc. undertakes no indebtedness to publicly update whatsoever
forward-looking statements, whether as a result of novel information, future
events or otherwise.
Micromet, Inc.
http://www.micromet-inc.com
More info
